GlassScriptPhysician profile
Tejas Jayendrabhai Modi
NPI 1912245267
$1,938.49
in general payments reported to CMS, 2019-2025
31 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $117 · 2022: $250 · 2023: $416 · 2024: $403 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.36 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $330.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $273.79 | 2020-2025 | Lynparza, Enhertu |
| Celgene Corporation | $203.75 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $135.42 | 2019-2025 | |
| Daiichi Sankyo INC. | $100.89 | 2024-2025 | Enhertu, Datroway, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $96.78 | 2019-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $94.58 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $89.62 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Tempus Ai, INC | $77.82 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $67.44 | 2019-2023 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $51.05 | 2024-2025 | Onivyde |
| Genzyme Corporation | $32.51 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $29.82 | 2022-2024 | Libtayo |
| Genmab U.S., INC. | $29.40 | 2023 | Tivdak |
| Incyte Corporation | $28.79 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $27.38 | 2019-2020 | |
| Astellas Pharma US INC | $27.10 | 2019-2024 | Xtandi |
| Global Blood Therapeutics, INC. | $25.30 | 2022 | |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Janssen Biotech, INC. | $24.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.89 | 2019 | |
| Puma Biotechnology, INC. | $18.96 | 2024 | |
| Abbvie INC. | $17.13 | 2022 | |
| Pharmaessentia USA Corporation | $15.64 | 2024 | Besremi |
| Beigene USA, INC. | $15.35 | 2023 | Brukinsa |
| Cti Biopharma Corp. | $15.32 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2019 | |
| Rigel Pharmaceuticals, INC. | $14.50 | 2022 | |
| Lilly USA, LLC | $12.89 | 2020 | |
| Emd Serono, INC. | $11.79 | 2020 | |
| Exelixis INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.